Category: Prostate Cancer

Twenty-five years ago, most men diagnosed with localized prostate cancer were pointed toward one thing: surgery. Today the picture looks entirely different, with focal treatments and Active Surveillance firmly in the mainstream. The shift was not driven by fashion. It came from advanced imaging, more accurate biopsy, and long-term trial data that changed the calculus. keep reading

Most men over 45 grew up hearing that masturbation caused everything from blindness to acne. Harvard researchers found something closer to the opposite: men who ejaculated 21 times a month had a lower risk of prostate cancer than men who managed 4 to 7. A follow-up look at gene activity in prostate tissue hints at why that might be true. keep reading

Did you know over 95% of prostate cancers share the same name—adenocarcinoma? This common cell type is usually slow-growing, but not always. Understanding how it develops, why PSA levels matter, and what early detection can reveal is key to knowing your best treatment options. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

There's a saying that less is more. For men with intermediate-risk prostate cancer weighing hormone therapy on top of radiation, that phrase turns out to be more than a proverb. Five-year results from a landmark 1,492-patient trial found better cancer control in the combined group, no survival difference, and a real cost in side effects. keep reading

Here's an uncomfortable truth: most elevated PSA tests turn out to be false alarms, yet they still steer hundreds of thousands of men toward a needle biopsy every year. A smarter path exists. By adding the Stockholm3 blood test and an MRI before anyone reaches for a needle, doctors can tell which men genuinely need a biopsy and which can safely wait, sparing a lot of worry and harm. keep reading

Guadeloupe, a small Caribbean island, has the highest prostate cancer incidence in the world, more than double the U.S. rate. Statistics like that aren't just trivia; they point toward causes. Pulled together by the World Cancer Research Fund, the global data keeps landing on the same message: excess body fat and poor diet raise risk, and healthier habits can lower it. keep reading

Months after finishing radiation for prostate cancer, many men watch their PSA tick upward and brace for the worst. Often, though, it's a false alarm: a 'PSA bounce' that settles on its own and may even signal a stronger response to treatment. The real task is telling a harmless bounce apart from a true recurrence, and a handful of clinical clues make that possible. keep reading

Only 16% of adult cancer patients in the U.S. meet national exercise guidelines. For men with early stage, low risk prostate cancer, that's a missed opportunity. Studies show active men delay reclassification on Active Surveillance far longer than sedentary men, and muscle mass may matter more for survival than body fat does. keep reading

For a decade, metformin carried a quiet reputation as a cancer fighter hiding in plain sight in millions of medicine cabinets. A rigorous new trial has now tested that reputation and come up short. The story is not quite finished, though. Buried in the fine print sits one group of men for whom the drug may have done something after all. keep reading